Here, we found that ML323 administration eliminates cancer stem cells increases CD8+ T cells infiltration simultaneously, and enhances the therapeutic efficacy of anti-CTLA4 antibody or 5-FU, demonstrating the great potential of ID1 as a dual-functional target. The gene discussed is CD8A; the disease is cancer.